# Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss

> **NCT00637572** · PHASE2 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 63 (actual)

## Conditions studied

- HIV Infections
- Cachexia
- Anorexia
- AIDS Wasting Syndrome
- HIV Wasting Syndrome

## Interventions

- **DRUG:** Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL
- **DRUG:** Megestrol acetate oral suspension 40 mg/mL

## Key facts

- **NCT ID:** NCT00637572
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2017-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00637572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00637572, "Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00637572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*